Healthcare / Medical Instruments & SuppliesNasdaqCM
$0.37
-0.00 (-1.06%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-19.3M · quality 71.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$23M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-317.4%
↓Gross Margin
62.0%
↑Debt/Equity
0.80
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
+17.2%
FCF CAGR
—
FCF margin
-842.5%
FCF / Net income
1.04x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.3M · net income $-18.6M · FCF $-19.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $2.3M | $2.3M | $1.6M | $1.1M | $1.2M | $1.2M | $1.0M |
| Net Income | $-18.6M | $-18.6M | $-18.8M | $-14.2M | $-11.4M | $-7.5M | $-6.9M |
| EBITDA | $-15.9M | $-15.9M | $-16.3M | $-13.2M | $-10.5M | $-7.7M | $-6.3M |
| EPS | — | — | -0.85 | -0.93 | -0.96 | -1.12 | -7.20 |
| Gross Margin | 62.0% | 62.0% | 66.6% | 64.5% | 63.4% | 68.6% | 70.5% |
| Operating Margin | -767.0% | -767.0% | -1091.8% | -1353.4% | -961.7% | -706.7% | -668.0% |
| Net Margin | -812.3% | -812.3% | -1155.0% | -1329.1% | -944.6% | -639.0% | -666.2% |
| Balance Sheet | |||||||
| Debt/Equity | 0.80 | 0.80 | 3.23 | 0.37 | 0.04 | — | — |
| Current Ratio | 4.53 | 4.53 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-19.3M | $-19.3M | $-20.3M | $-11.4M | $-11.1M | $-8.2M | $-4.9M |
| Returns | |||||||
| ROE | -317.4% | -317.4% | -816.5% | -77.6% | -74.8% | -28.6% | 13.3% |
| Valuation | |||||||
| P/B | 3.80 | 3.80 | 10.82 | 0.79 | 0.76 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | 40.8% | 40.8% | 52.0% | -11.1% | — | 13.7% | — |
| EPS Growth | — | — | 8.6% | 3.1% | — | 84.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-54.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.85 → n/d
Residual
-54.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.